 Compound therapies combine antibodies to suppress multiple defensive layers.Known checkpoints include CTLA-4 targeted by ipilimumab, PD-1 targeted by nivolumab and pembrolizumab and the tumor microenvironment.The tumor microenvironment (TME) features prevents the recruitment of T cells to the tumor.